Holen Sie sich die Stockscreener-App
16.95
3.15%
-0.845
Handel nachbörslich:
16.47
-0.475
-2.80%
Sensei Biotherapeutics Inc Aktie (SNSE) Neueste Nachrichten
Sensei Biotherapeutics Inc. (SNSE) Q1 2026 Earnings: Deep EPS Miss Reflects Heavy R&D Investment and Pre-Revenue StatusDiluted EPS Report - Newser
SNSE Q1 2026 Earnings: EPS Significantly Below Estimates as Company Invests in PipelineCommunity Buy Signals - Newser
SNSE Initiated Coverage by Citigroup -- Rating Set to Buy with $55 Target - GuruFocus
Sensei Biotherapeutics Updates 2026 Board Reconstitution Plans - TipRanks
Sensei Biotherapeutics (SNSE) revises 2026 board reconstitution timeline - Stock Titan
Sensei Biotherapeutics (SNSE) Q1 2026 Earnings: Massive EPS Miss Overshadowed by Upbeat SentimentReal Trader Network - Newser
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200 Million and Issues Series B Preferred Stock Conversion to Common Shares 1 - Minichart
Sensei Biotherapeutics Sets Vote on Series B Conversion - TipRanks
Sensei Biotherapeutics to Convert Series B Preferred, Pro Forma Shows 25.7M Shares and $184.6M Equity - TradingView
$200M financing and Faeth deal reshape Sensei Biotherapeutics (NASDAQ: SNSE) - Stock Titan
SNSE SEC FilingsSensei Biotherapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
How Should Investors Value Sensei Biotherapeutics (SNSE) After Q - GuruFocus
Sensei Biotherapeutics Analyst Ratings and Price Targets | NASDAQ:SNSE - Benzinga
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - BioSpace
Sensei Biotherapeutics stock (US81728A1088): Q1 results and corporate update draw focus - AD HOC NEWS
Is Sensei Biotherapeutics (SNSE) Attractive After Q1 2026? EPS - GuruFocus
Millennium management reports $89k Sensei Biotherapeutics share sales - Investing.com
Millennium management reports $89k Sensei Biotherapeutics share sales By Investing.com - Investing.com South Africa
Millennium entities (SNSE) net sell 12,861 Sensei Biotherapeutics shares - Stock Titan
Sensei Biotherapeutics (SNSE) stake by Millennium entities hits 147,731 shares - Stock Titan
[Form 4] Sensei Biotherapeutics, Inc. Insider Trading Activity - Stock Titan
Millennium entities disclose 127,095 Sensei Biotherapeutics (SNSE) shares - Stock Titan
Sensei Biotherapeutics, Inc. Q1 2026 10-Q Filing: Financial Statements, Risk Factors, and Management Analysis - Minichart
Sensei Biotherapeutics (NASDAQ: SNSE) joint holders report 128,761 shares (9.6%) - Stock Titan
Transformative Quarter for Sensei Biotherapeutics (SNSE) - GuruFocus
Sensei Biotherapeutics Reports Q1 2026 Financial Results, Highlights PIKTOR Clinical Progress and Faeth Acquisition - Minichart
Sensei Biotherapeutics 1Q Research and Development Expenses $18.0M >SNSE - Moomoo
StemPoint (SNSE) and Michelle Ross report 9.9% stake in Sensei - Stock Titan
Sensei Biotherapeutics Releases Q1 2026 Financial Results - AlphaStreet
[SCHEDULE 13G] Sensei Biotherapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Sensei Biotherapeutics, Inc. 1Q 2026: Net income $(170.2M), EPS $(131.45) — 10-Q Summary - TradingView
SNSE: Faeth acquisition and $200M raise drive pipeline expansion; net loss rises on one-time costs - TradingView
Sensei Biotherapeutics reports $170.2M Q1 net loss, $202.8M cash position - TradingView
Sensei Biotherapeutics (SNSE) absorbs Faeth acquisition, $200M raise and going-concern risk - Stock Titan
Sensei Biotherapeutics (Nasdaq: SNSE) Q1 loss reflects Faeth acquisition impact - Stock Titan
Press Release: Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
Sensei Biotherapeutics reports Q1 2026 loss on Faeth charges - grafa.com
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies - GlobeNewswire Inc.
TradingKey - TradingKey
Sensei Biotherapeutics Secures 200 Million Dollars for Oncology Pipeline - HarianBasis.co
Sensei Biotherapeutics (SNSE): Best Performing NASDAQ Stocks According to Wall Street Analysts - Insider Monkey
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer - PharmiWeb.com
Sensei Biotherapeutics announces first patient dosed in FTH-PIK-101 trial - TipRanks
The competitive edge that makes Sensei Biotherapeutics (SNSE) special (-3.15%) 2026-05-05Most Discussed Stocks - newser.com
Sensei Biotherapeutics begins trial of PIKTOR in breast cancer By Investing.com - Investing.com South Africa
Sensei Biotherapeutics begins trial of PIKTOR in breast cancer - Investing.com
10 Best Performing NASDAQ Stocks According to Wall Street Analysts - Insider Monkey
Short Selling Surges in Small-Cap Healthcare Stocks Amid Bearish Sentiment - GuruFocus
Sensei Biotherapeutics Inc expected to post a loss of 62 cents a shareEarnings Preview - TradingView
[144] Sensei Biotherapeutics, Inc. SEC Filing - Stock Titan
Sensei Biotherapeutics (SNSE) price target increased by 53.85% to 51.00 - MSN
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):